CN104352616A - 治疗坐骨神经痛的中药组合物及其制备方法 - Google Patents
治疗坐骨神经痛的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104352616A CN104352616A CN201410595382.7A CN201410595382A CN104352616A CN 104352616 A CN104352616 A CN 104352616A CN 201410595382 A CN201410595382 A CN 201410595382A CN 104352616 A CN104352616 A CN 104352616A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- sciatica
- herba
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 208000008765 Sciatica Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 241000117410 Glechoma biondiana Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000012567 medical material Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000706 filtrate Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 241001252601 Blumea Species 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 241001127579 Flemingia philippinensis Species 0.000 abstract description 2
- 240000004836 Justicia adhatoda Species 0.000 abstract description 2
- 241001079002 Melicope pteleifolia Species 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 44
- 238000012360 testing method Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002674 ointment Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 229940040145 liniment Drugs 0.000 description 9
- 239000000865 liniment Substances 0.000 description 9
- 238000001467 acupuncture Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229940098465 tincture Drugs 0.000 description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000001624 hip Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960003639 laurocapram Drugs 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 201000003068 rheumatic fever Diseases 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003961 penetration enhancing agent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 tincture Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 240000000275 Persicaria hydropiper Species 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241001079251 Euodia Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241001391115 Gelsemium elegans Species 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000123868 Justicia ventricosa Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001210457 Medicago prostrata Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000017337 Persicaria hydropiper Nutrition 0.000 description 1
- 241001106412 Pilea Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001604597 Pyrestini Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000227643 Symmeria Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003239 pyrrolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗坐骨神经痛的中药组合物及其制备方法。该中药是由包括如下重量份的原料制备而成的:三叉苦、九节风、大风艾、白透骨消、辣蓼、大驳骨、千斤拔。本发明还提供了这种中药组合物的制备方法。本发明提供的中药组合物在治疗坐骨神经痛方面,疗效确切、安全性好、没有副作用,且使用方便、成本低,效果优于现有技术。
Description
技术领域
本发明涉及中药领域,具体涉及一种治疗坐骨神经痛的中药组合物及其制备方法。
背景技术
坐骨神经痛是以坐骨神经径路及分布区域疼痛为主的综合征。坐骨神经痛的绝大多数病例是继发于坐骨神经局部及周围结构的病变对坐骨神经的刺激压迫与损害,称为继发坐骨神经痛;少数系原发性,即坐骨神经炎。坐骨神经痛绝大多数是由腰椎病变引起的,主要是腰椎间盘突出和椎管狭窄,也有些早期的腰椎间盘退变会导致坐骨神经痛。上班族久坐导致神经压迫。
治疗坐骨神经痛的西药通常采用止痛剂、维生素B族及短程皮质类固醇激素,可在一定程度上缓解坐骨神经痛的症状,但是无法达到根治的目的,对于一些重症坐骨神经痛患者可采用此方法缓解,口服这类药物不宜过多,否则对自己的肝脏和肾脏都会带来太大的影响。
手术疗法虽效果显著,术后可明显减轻患者的疼痛感受,但在长期的实践应用中,手术后患者病痛反弹,痛苦不堪的弊端日益显露,疗效不甚满意。非手术治疗,是众多人的首选,中医药针对坐骨神经痛疗效显著,是治疗坐骨神经痛较好的治疗方法。坐骨神经痛是坐骨神经通路及其分布区的疼痛综合征,属中医骨科范畴。其中医分型与中药治法:
1、风寒湿邪,闭阻经络。症见下肢疼痛,活动或受凉后加重,呈持续性钝痛或伴阵发性加剧,加剧时疼痛可呈烧灼或刀害虫样,夜间尤甚,肌肉麻木不仁,舌质淡、苔薄白,脉弦紧。治法采用袪风胜湿,温经散寒之法。
2、气虚血瘀,脉络阻滞。症见一侧腰腿作痛,疼痛绵绵不已,明轻时重,下肢麻木,屈伸不利,痛点不利,痛点固定不移,入夜尤甚。舌质紫暗,脉多弦涩。治法应用益气活血,养血通络之法、
3、肝肾亏虚,寒湿侵袭。症见一侧腰腿作痛,咳嗽、喷嚏、用力排便时疼痛加剧,伴小腿麻木、发凉,畏寒喜温,舌质淡,苔薄白,脉沉或沉细。治法采用温肾养肝,疏风散寒,祛湿通络之法。
发明内容
本发明的目的是提供一种治疗坐骨神经痛的中药组合物;
本发明的另一目的是提供一种治疗坐骨神经痛的中药组合物的制备方法。
本发明的目的是通过下列的技术方案实现的:
本发明所述的治疗坐骨神经痛的中药组合物,是由包括如下重量份的原料制备而成的:
三叉苦15-50份,九节风5-30份,大风艾20-50份,白透骨消15-40份,辣蓼20-50份,大驳骨20-50份,千斤拔20-50份。
优选的,是由包括如下重量份的原料制备而成的:
三叉苦20-40份,九节风10-20份,大风艾30-40份,白透骨消20-30份,辣蓼30-40份,大驳骨30-40份,千斤拔30-40份。
更优的,是由包括如下重量份的原料制备而成的:
三叉苦30份,九节风15份,大风艾35份,白透骨消25份,辣蓼35份,大驳骨35份,千斤拔35份。
以下是本发明中药制剂的药材来源:
三叉苦,芸香科吴茱萸属植物三叉苦Evodia lepta (Spreng.)Merr.,以根及叶入药。 苦,寒。清热解毒、散瘀止痛。防治流行性感冒、流行性脑脊髓膜炎、乙型脑炎、中暑,治感冒高热,扁桃体炎,咽喉炎,肺脓疡,肺炎,疟疾,风湿性关节炎,坐骨神经痛,腰腿痛,胃痛,黄疸型肝炎,断肠草(钩吻)中毒。外用治跌打扭伤,虫蛇咬伤,痈疖肿毒,外伤感染,湿疹,皮炎。
九节风,荨麻科九节风Pilea symmeria Wedd. var. salwinensis Hand.-Mazz.,以全草入药。 微苦、涩,温。散瘀,止痛,软坚,活血。主治跌打损伤,骨癌,骨折。
大风艾,为菊科艾纳香属植物大风艾Blumea balsamifera DC.,以根、嫩枝、叶入药。 辛、微苦,微温。祛风消肿,活血散瘀。用于感冒,风湿性关节炎,产后风痛,痛经;外用治跌打损伤,疮疖痈肿,湿疹,皮炎。
白透骨消,为唇形科杆物白透滑消的全草。 味辛,性温。祛风活血;利湿解毒。主风湿痹痛;跌打损伤;肺痈;黄疸;急性肾炎;尿道结石;痄腮。
辣蓼,蓼科蓼属植物辣蓼Polygonum flaccidum Meism及水蓼P.hydropiper L.,以全草或根、叶入药。辛,温。祛风利湿,散瘀止痛,解毒消肿,杀虫止痒。用于痢疾,胃肠炎,腹泻,风湿关节痛,跌打肿痛,功能性子宫出血;外用治毒蛇咬伤,皮肤湿疹。
大驳骨,为爵床科鸭嘴花属植物大驳骨Admatoda ventricosn (Wall.) Nees [Justicia ventricosa Wall.;Cendarussa ventricosa (Wall.) Nees],以全株入药。辛、微酸、平。活血散瘀,祛风除湿。骨折,跌打损伤,风湿性关节炎,腰腿疼,外伤出血。
千斤拔,为豆科千斤拔属植物千斤拔Moghania philippinensis (Merr. et Rolfe) Li [M. prostrata (Roxb.) Wang et Tang],以根入药。 甘、微温,平。祛风湿,强腰膝。用于风湿性关节炎,腰腿痛,腰肌劳损,白带,跌打损伤。
本发明的另一方面是提供了本发明中药组合物的活性成分的制备方法,该方法是采用采用水提或40-80%体积百分浓度的乙醇提取制备而成。具体制备方法如下:
方案一:取全部7味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
方案二:取全部7味药材,混合后用40-80%乙醇回流提取2-3次,每次乙醇用量为药材总量的4-10倍,提取时间为1-4小时,合并提取液,过滤,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
方案三:取全部7味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,加入乙醇,使含醇量为40-70%,静置12-24小时,滤过,滤液浓缩至70-80℃时相对密度为1.10-1.25的浸膏,即得活性成分。
本发明所述的治疗坐骨神经痛的中药组合物,可以与医药学上可接受的载体配合,制成各种常用制剂,如外用搽剂、洗剂、酊剂、油剂、糊剂、(软)膏剂、熨剂等。
本发明的药学上可接受的载体包括但不限于以下:
外用制剂
稀释剂:蒸馏水、乙醇等。
助溶剂:甘油、山梨醇等多元醇。
防腐剂:苯甲酸、苯甲酸钠、丙酸、尼泊金类、对羟基苯甲酸乙酯等。
油脂性基质:凡士林、液状石蜡、羊毛脂、蜂蜡、动物油、植物油、单硬脂酸甘油酯、十八醇等及其混合物、
水溶性基质:甘油、海藻酸钠、卡巴浦尔树脂、淀粉明胶、甲基纤维素、羧甲基纤维素钠、聚乙二醇、聚乙烯醇。
促透剂:角质保湿利尿素、吡咯酮类衍生物、亚油酸、月桂醇、吐温、十二烷基三甲基溴化铵、十二烷基磺酸钠、十二烷基硫酸钠、薄荷醇、月桂氮卓酮(氮酮)等。
例如,其可以通过下列方法之一制备为各种常见剂型:
方法1:酊剂
取方案一至方案三所得活性成分之一,加入乙醇,搅匀,静置过滤后,配制成一定醇浓度的溶液,即得。
方法2:搽剂
取方案一至方案三所得活性成分之一,加入搽剂常用辅料,按常规生产方法制备得本发明搽剂。
上述搽剂常用辅料包括稀释剂、防腐剂、助溶剂、促透剂之一或全部。
方法3:膏剂
取方案一至方案三所得活性成分之一,加入膏剂常用辅料,按常规生产方法制备得本发明膏剂。
上述膏剂常用辅料包括油脂性基质、水溶性基质、防腐剂、促透剂之一或全部。
方法4:凝胶剂
取方案一至方案三所得活性成分之一,浓缩后与常用凝胶基质混合,按常规生产方法制备得本发明凝胶剂。
上述凝胶常用基质包括卡波姆、明胶、黄蓍胶、纤维素类和泊洛沙母等,还可加促透剂、助溶剂、稀释剂之一或全部。
方法5:粉剂
取全部药材粉碎成粗粉,过80-100目筛,即得本发明粉剂。
本申请人在研究传统中医辨证治疗的基础上参考现代药理研究成果,经过多年的试验,将多种配方进行筛选,找到了相互配合具有很好祛风胜湿、活血通络功效的中药组合物。
本发明配方合理创新,三叉苦活血止痛、清热解毒;九节风软坚散瘀、活血止痛;大风艾祛风活血、消肿散瘀;白透骨消祛风活血、利湿解毒;辣蓼祛风利湿、散瘀止痛、解毒消肿;大驳骨活血散瘀、祛风除湿;千斤拔祛风湿,强腰膝。全方祛风胜湿、活血通络,用于治疗风寒湿邪,气虚血瘀,经脉阻闭引起的坐骨神经痛疗效极佳。本发明技术方案符合中医辨证施治的机理,立足疾病之本源,组方合理科学。
本发明提供的一种治疗坐骨神经痛的中药组合物具有以下优点:
1、本发明提供的组合物安全有效,有祛风胜湿、活血通络的作用,对风寒湿邪,气虚血瘀,经脉阻闭引起的坐骨神经痛疗效极佳。
2、本发明中药组合物对坐骨神经痛的疗效较显著,配合传统中医针刺治疗20天后总有效率达90%,显著高于单独使用传统中医针刺疗法(总有效率为70%)。
3、本发明中药组合物配方合理创新,生产成本低、工艺简单。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是,本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。除非另有说明,本发明中的乙醇量的百分数是体积百分数,v/v表示溶液的体积比。
实施例1 搽剂
三叉苦5kg,九节风3kg,大风艾5kg,白透骨消4kg,辣蓼5kg,大驳骨5kg,千斤拔5kg。取7味药材,加水提取2次,两次加水量分别为药材总重量的10倍、8倍,两次提取时间分别为2小时、1小时,合并提取液,滤过,滤液浓缩至80℃时相对密度为1.10的浸膏,加入0.1%的苯甲酸钠、0.05%的尼泊金甲酯,混匀,分装,即得本发明搽剂。
实施例2搽剂
三叉苦1.5kg,九节风0.5kg,大风艾2kg,白透骨消1.5kg,辣蓼2kg,大驳骨2kg,千斤拔2kg。取7味药材,用40%乙醇回流提取3次,每次乙醇用量分别为药材总量的10倍、8倍、4倍,提取时间分别3小时、2小时、1小时,合并提取液,过滤,滤液浓缩60℃时相对密度为1.25的浸膏,加入0.1%的苯甲酸钠、0.05%的尼泊金甲酯,混匀,分装,即得本发明搽剂。
实施例3 膏剂
三叉苦20g,九节风10g,大风艾30g,白透骨消20g,辣蓼30g,大驳骨30g,千斤拔30g。取7味药材,加水提取3次,三次加水量分别相当于药材总重量的12倍、8倍、6倍,每次提取时间分别3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.20的清膏,加入乙醇,使含醇量为40%,静置24小时,滤过,滤液浓缩至滤液浓缩至70℃时相对密度为1.10的浸膏,备用。
称取硬脂酸15g,凡士林100g,羊毛脂80g,硬脂酸甘油脂35g,十六醇80g ,加热至85℃,搅匀,作为油相,备用;另取甘油130g,对羟基苯甲酸乙酯2g,十二烷基硫酸钠20g,月桂氮卓酮25g,加入上述浸膏,用水调节使油、水两相共1000g,作为水相,加热至90℃,待全部溶解后,恒温至85℃,搅匀;将油相缓缓加入水相,置匀浆机中搅拌,冷却,凝固,分装,即得本发明膏剂。
实施例4 膏剂
三叉苦40g,九节风20g,大风艾40g,白透骨消30g,辣蓼40g,大驳骨40g,千斤拔40g。取7味药材,用乙醇回流提取2次,每次乙醇浓度分别为80%、60%,每次乙醇用量分别为药材总量的10倍、8倍,提取时间分别为4小时、3小时,合并提取液,过滤,滤液浓缩至80℃时相对密度为1.10的浸膏,备用。
称取硬脂酸10g,凡士林95g,羊毛脂85g,硬脂酸甘油脂40g,十六醇80g,加热至85℃,搅匀,作为油相,备用;另取甘油120g,对羟基苯甲酸乙酯3g,十二烷基硫酸钠25g,月桂氮卓酮30g,加入上述浸膏,用水调节使油、水两相共1000g,作为水相,加热至90℃,待全部溶解后,恒温至85℃,搅匀;将油相缓缓加入水相,置匀浆机中搅拌,冷却,凝固,分装,即得本发明膏剂。
实施例5 凝胶剂
三叉苦30g,九节风15g,大风艾35g,白透骨消25g,辣蓼35g,大驳骨35g,千斤拔35g。取7味药材,三次加水量分别为药材总重量的12倍、8倍、6倍,三次提取时间分别为3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.25的浸膏,备用。
将卡波姆10g撒于适量的蒸馏水中,充分溶胀,加入丙二醇100g,月桂氮卓酮10g研磨使润湿,加10g三乙醇胺研磨成透明凝胶基质,水浴至70℃。取100g丙二醇、10g吐温-80混合加热溶解后,将上述浸膏加入到基质中,慢加快搅,加蒸馏水至1000g,继续搅拌均匀,得黄棕色透明凝胶剂。
实施例6凝胶剂
三叉苦35g,九节风25g,大风艾25g,白透骨消35g,辣蓼45g,大驳骨25g,千斤拔35g。取7味药材,每次加水量分别相当于药材总重量的12倍、10倍,每次提取时间分别为3小时、2小时,合并提取液,滤过,滤液浓缩至80℃下相对密度为1.05的清膏,加入乙醇,使含醇量为70%,静置12小时,滤过,滤液浓缩至70℃时相对密度为1.25的浸膏,备用。
将卡波姆10g撒于适量的蒸馏水中,充分溶胀,加入甘油和丙二醇各50g,月桂氮卓酮12g研磨使润湿,加8g三乙醇胺研磨成透明凝胶基质,水浴至70℃。取100g丙二醇、10g吐温-80混合加热溶解后,将上述浸膏加入到基质中,慢加快搅,加蒸馏水至1000g,继续搅拌均匀,得黄棕色透明凝胶剂。
实施例7 酊剂
三叉苦25g,九节风25g,大风艾45g,白透骨消25g,辣蓼25g,大驳骨30g,千斤拔30g。取7味药材,两次加水量分别为药材总重量的10倍、8倍,两次提取时间分别为2小时、1小时,合并提取液,滤过,滤液浓缩至80℃时相对密度为1.10的浸膏。加入浸膏重量3倍的体积百分比为95%的乙醇,搅匀,静置24小时,滤过,滤液加纯净水调至含醇量为60%,搅匀,静置12h,精滤,分装,即得本发明酊剂。
实施例8 酊剂
三叉苦20g,九节风20g,大风艾30g,白透骨消15g,辣蓼40g,大驳骨33g,千斤拔30g。取7味药材,三次加水量分别相当于药材总重量的12倍、8倍、6倍,每次提取时间分别3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.25的浸膏,加入浸膏重量3倍的体积百分比为85%的乙醇,搅匀,静置24小时,滤过,滤液加纯净水调至含醇量为70%,搅匀,静置12h,精滤,分装,即得本发明酊剂。
实施例9粉剂
三叉苦35g,九节风35g,大风艾30g,白透骨消35g,辣蓼50g,大驳骨20g,千斤拔50g。药材净选、粉碎,过80-100目筛,即得本发明粉剂。
使用时,加入1倍量的沸水,浸泡15分钟后敷于患处即可。
临床试验
一、对坐骨神经痛治疗的临床观察
1 一般资料
选择120 例坐骨神经疼痛患者为研究对象。其中,男67例,女53例。年龄30~67岁,平均(47.4±5.2)岁。病程7d~3个月。120例患者中,50例诊断为腰骶关节退行性变,23 例为隐性骶裂,20例诊断为腰骶纤维组织炎,17例为腰椎间盘脱出,10例为梨状肌损伤。患者临床主要表现为不同程度的一侧或两侧大腿后外侧、小腿外侧放射样痛,伴有突发性臀腿刀割样剧痛,腰部活动受限,夜不能寐。轻者跛行,重者步履艰难,行走困难。随机将120例患者分为3组,即实验一组40例,实验二组40例,对照组40例,3组患者性别、年龄、病情、病程以及体征等一般资料上,差异均无统计学意义 ( P>0.05),具有可比性。
2 药物制备
实验一组:本发明实施例4膏剂。
实验二组:三叉苦2.3kg,黑老虎2.3kg、海桐皮2.3kg、岗梅1.5kg、黄柏1kg、枫荷梨3.5kg、络石藤1kg、走马胎2.3kg、五加皮1kg、七叶莲1.5kg、鸡血藤1.2kg、黑血藤2.3kg、虎杖1.2kg、杜仲0.7kg、金樱根2.3kg、桂枝0.6kg。取16味药材,三次加水量分别为药材总重量的12倍、8倍、6倍,三次提取时间分别为3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.25的清膏,加入辅料淀粉、乙醇、滑石粉,制得片剂。
3 治疗方法
对照组40例患者行中医针刺治疗。指导患者取侧卧位,选取患者臀部和股后部疼痛最明显的2~3处为进针点,对坐骨神经干垂直刺入,当触及骨质时,退出针至组织浅层。再改变针刺方向,顺坐骨神经走行方向试行扇形针刺。1次/d,10天为 1 疗程。
实验一组40例患者在对照组中医针刺治疗的基础上贴上述制备的膏剂,1贴/次,2次/d, 10天为 1 疗程。
实验二组40例患者在对照组中医针刺治疗的基础上服用本发明实施例5制备的片剂,2片/次,3次/d,10天为 1 疗程。
4 疗效评价
于2个疗程后,分别对3组患者的临床治疗效果进行评价,痊愈: 临床症状及体征全部消失,功能活动不受限,功能恢复; 显效: 临床症状及体征基本消失,功能活动不受限,但劳累过后有轻微不适感,功能恢复; 有效: 疼痛症状减轻,功能活动仍有受限; 无效: 患者临床症状及体征无变化,甚至加重。临床治疗的总有效率 = 痊愈率 + 显效率 + 有效率。
4 疼痛评价
治疗后的疼痛程度 采用视觉模拟评分法(VAS)分别对3组患者治疗后的疼程度进行评定。VAS 方法下疼痛评价级别分为4级,无痛(0分): 无疼痛感受; 轻度疼痛(1~4分): 疼痛感受较轻,可保证正常的睡眠; 中度疼痛(5~7分): 疼痛明显,不能忍受,影响正常睡眠; 重度疼痛(8~10分): 疼痛剧烈,不能忍受,严重影响正常睡眠。
5 结果
5.1 三组患者临床治疗效果对比分析,见表 1。
表1三组患者临床治疗坐骨神经痛疗效分析
组别 | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) |
对照组 | 40 | 10 | 8 | 10 | 12 | 70 |
实验一组 | 40 | 16 | 10 | 10 | 4 | 90* |
实验二组 | 40 | 16 | 12 | 9 | 3 | 92.5* |
注:与对照组相比,* P<0.01
由表1可知,实验一组患者临床治疗的总有效率为90%,实验二组患者临床治疗的总有效率为92.5%,对照组为70%,两组实验组与对照组比较,差异具有统计学意义 (P<0.01)。结果显示:本发明配合传统中医针刺对坐骨神经痛的治疗有显著作用。
5.2 两组患者治疗后的疼痛程度对比分析,见表2。
表2 两组患者的夜间疼痛程度比较(例/%)
组别 | 例数 | 重度 | 中度 | 轻度 | 无痛 | 无痛+轻度 |
对照组 | 40 | 4/10% | 8/20% | 25/62.5% | 3/7.5% | 28/71.67% |
实验一组 | 40 | 1/2.5% | 2/5% | 27/67.5% | 10/25% | 37/92.5%* |
实验二组 | 40 | 0 | 1/2.5% | 28/70% | 11/27.5% | 39/97.5%* |
注:与对照组相比,* P<0.01
由表2可知,实验一组患者治疗后无痛和轻度疼痛的总比率为92.5%,实验二组患者治疗后无痛和轻度疼痛的总比率为97.5%,对照组为71.67%,两组实验组与对照组比较,差异具有统计学意义(P<0.01)。实验一组患者治疗后无痛和轻度疼痛的总比率明显高于对照组。结果表明: 经本发明治疗后,实验一组患者的总体疼痛程度要轻于对照组。
典型病例
王XX,女,57岁。主诉右下肢疼痛,持续20天,影响工作生活。畏寒,口干较重,大便困难,舌质红苔白厚腻,脉缓。患者一直服用布洛芬等药物,当停药即疼痛加重。查体:右下肢直腿抬高试验阳性。诊断:右侧坐骨神经痛。给予本发明实施例7酊剂外搽10天后腰腿疼痛明显减轻,大便通畅,继续治疗10天疼痛轻微,工作生活不受妨碍,再巩固治疗10天,至大寒节气,而疼痛未再复发。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种治疗坐骨神经痛的中药组合物,其特征在于它是包括由如下重量份的原料制备而成的:
三叉苦15-50份,九节风5-30份,大风艾20-50份,白透骨消15-40份,辣蓼20-50份,大驳骨20-50份,千斤拔20-50份。
2.如权利要求1所述的中药组合物,其特征在于它是由包括如下重量份的原料制备而成的:
三叉苦20-40份,九节风10-20份,大风艾30-40份,白透骨消20-30份,辣蓼30-40份,大驳骨30-40份,千斤拔30-40份。
3.如权利要求1所述的中药组合物,其特征在于它是由包括如下重量份的原料制备而成的:
三叉苦30份,九节风15份,大风艾35份,白透骨消25份,辣蓼35份,大驳骨35份,千斤拔35份。
4.如权利要求1-3任一项所述的治疗坐骨神经痛的中药组合物,其特征在于它的活性成分是采用水提或40-80%体积百分浓度的乙醇提取制备而成。
5.如权利要求4所述的治疗坐骨神经痛的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部7味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
6.如权利要求4所述的治疗坐骨神经痛的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部7味药材,混合后用40-80%乙醇回流提取2-3次,每次乙醇用量为药材总量的4-10倍,提取时间为1-4小时,合并提取液,过滤,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
7.如权利要求4所述的治疗坐骨神经痛的的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部7味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,加入乙醇,使含醇量为40-70%,静置12-24小时,滤过,滤液浓缩至70-80℃时相对密度为1.10-1.25的浸膏,即得活性成分。
8.一种治疗坐骨神经痛的中药组合物,由权利要求1-3中任一项所述的治疗坐骨神经痛的中药组合物与医药学上可接受的载体配合制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410595382.7A CN104352616A (zh) | 2014-10-30 | 2014-10-30 | 治疗坐骨神经痛的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410595382.7A CN104352616A (zh) | 2014-10-30 | 2014-10-30 | 治疗坐骨神经痛的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104352616A true CN104352616A (zh) | 2015-02-18 |
Family
ID=52519989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410595382.7A Pending CN104352616A (zh) | 2014-10-30 | 2014-10-30 | 治疗坐骨神经痛的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104352616A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104815078A (zh) * | 2015-04-25 | 2015-08-05 | 于巧媛 | 一种治疗湿热侵络型坐骨神经痛的中药组合物 |
CN105232736A (zh) * | 2015-10-16 | 2016-01-13 | 庞泽文 | 一种缓解坐骨神经痛的中草药组合物 |
CN105232664A (zh) * | 2015-10-16 | 2016-01-13 | 庞泽文 | 一种外敷坐骨神经的膏贴 |
CN109528486A (zh) * | 2019-01-15 | 2019-03-29 | 河南羚锐制药股份有限公司 | 一种自热无烟型艾灸贴 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008247854A (ja) * | 2007-03-30 | 2008-10-16 | Shiseido Co Ltd | 抗酸化剤、dna損傷抑制剤および皮膚外用剤 |
CN101745079A (zh) * | 2010-01-28 | 2010-06-23 | 广西方略药业集团有限公司 | 具有祛风除湿、消肿止痛的透皮贴剂及其制备方法 |
-
2014
- 2014-10-30 CN CN201410595382.7A patent/CN104352616A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008247854A (ja) * | 2007-03-30 | 2008-10-16 | Shiseido Co Ltd | 抗酸化剤、dna損傷抑制剤および皮膚外用剤 |
CN101745079A (zh) * | 2010-01-28 | 2010-06-23 | 广西方略药业集团有限公司 | 具有祛风除湿、消肿止痛的透皮贴剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
中国药材公司: "《中国民间单验方》", 31 October 1994, 科学出版社 * |
刘方等: "跌打药酒的制备及质量控制", 《中医药学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104815078A (zh) * | 2015-04-25 | 2015-08-05 | 于巧媛 | 一种治疗湿热侵络型坐骨神经痛的中药组合物 |
CN105232736A (zh) * | 2015-10-16 | 2016-01-13 | 庞泽文 | 一种缓解坐骨神经痛的中草药组合物 |
CN105232664A (zh) * | 2015-10-16 | 2016-01-13 | 庞泽文 | 一种外敷坐骨神经的膏贴 |
CN109528486A (zh) * | 2019-01-15 | 2019-03-29 | 河南羚锐制药股份有限公司 | 一种自热无烟型艾灸贴 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100375634C (zh) | 一种用于艾灸的药物及其制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN104815295A (zh) | 一种治疗颈椎病的中药制剂 | |
CN104352616A (zh) | 治疗坐骨神经痛的中药组合物及其制备方法 | |
CN105687409A (zh) | 一种砭石泥灸及其制备方法 | |
KR20100079858A (ko) | 천연광물과 한약재를 주원료로 한 피부질환 치료용 외용제 | |
CN104740583A (zh) | 一种用于缓解克罗恩病的中药制剂及其制备方法 | |
CN104623376B (zh) | 用于治疗三叉神经痛的药物 | |
CN105343660A (zh) | 一种治疗周围性眩晕的中药制剂及其制造方法 | |
CN104324119A (zh) | 一种治疗坐骨神经痛的中药组合物及其制备方法 | |
CN109078105A (zh) | 一种治疗风湿类风湿关节炎、颈肩腰腿痛的中药组合物 | |
CN112870286B (zh) | 治疗特应性皮炎的中药组合物、制备方法及其应用 | |
CN104740208A (zh) | 一种用于治疗三叉神经痛的中药制剂及制备方法 | |
CN104784346A (zh) | 一种治疗瘙痒症的中药洗剂制备方法 | |
CN114306442A (zh) | 一种治疗特应性皮炎的中药组合物及其应用 | |
CN105232664A (zh) | 一种外敷坐骨神经的膏贴 | |
CN102579607B (zh) | 一种治疗痤疮的中药组合物 | |
CN105456923A (zh) | 一种祛瘀止痛的中药组合物及其制备方法 | |
CN104984310A (zh) | 一种治疗骨性关节炎的中药组合物及其制备方法 | |
CN104971286A (zh) | 一种治疗肩腰腿不适症的中药组合物 | |
CN113230365B (zh) | 一种治疗关节骨病的中药组合物、制剂及其制备方法和应用 | |
CN103285182B (zh) | 一种治疗皮肤病的外用药膏及制备方法 | |
CN106729443A (zh) | 一种用于消肿止痛的中药组合物及其制备方法 | |
CN106667851A (zh) | 一种中药祛痘乳及其制备方法 | |
CN105412395A (zh) | 一种治疗骨质增生的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150218 |